Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond
- 4 January 2024
- book chapter
- Published by Elsevier
- Vol. 140, 157-198
Abstract
No abstract availableKeywords
This publication has 166 references indexed in Scilit:
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T CellsClinical Cancer Research, 2013
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting CellsPLOS ONE, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactorJournal of Translational Medicine, 2012
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human MelanomasCancer Research, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Lentiviral vectors for immune cells targetingImmunopharmacology and Immunotoxicology, 2010
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific FvProtein Engineering, Design and Selection, 1994